FGFR3 and neoplasm: In a phase II trial, erdafitinib, a potent tyrosine kinase inhibitor of FGFR 1–4, was found to be associated with an objective tumor response in 40% of previously treated patients who had locally advanced and unresectable or metastatic urothelial carcinoma with at least one FGFR3 mutation or FGFR2/3 fusion.29